Pulse Biosciences, Inc. is a bioelectric medicine company. The Company’s proprietary CellFX nsPFA technology delivers nanosecond pulses of electrical energy to non-thermally clear cells while sparing adjacent noncellular tissue. The Company is engaged in the development of its CellFX nsPFA technology for use in the treatment of atrial fibrillation and in a select few other markets where it could have a profound positive impact on healthcare for both patients and providers. The Company’s Nano-pulse Stimulation (NPS) technology is an energy modality that delivers nanosecond-duration pulses of electrical energy, each less than a millionth of a second long, to non-thermally clear targeted cells while sparing adjacent noncellular tissue. The Company has designed a variety of applicators, or end-effectors, to explore the potential use of the CellFX platform to treat disorders in other medical specialties, such as cardiology, gastroenterology, gynecology, and ear, nose, and throat.
Código da empresaPLSE
Nome da EmpresaPulse Biosciences Inc
Data de listagemMay 18, 2016
CEOMr. Paul A. Laviolette
Número de funcionários75
Tipo de títulosOrdinary Share
Fim do ano fiscalMay 18
Endereço3957 Point Eden Way
CidadeHAYWARD
Bolsa de valoresNASDAQ Capital Market Consolidated
PaísUnited States of America
Código postal94545
Telefone15109064600
Sitehttps://www.pulsebiosciences.com/
Código da empresaPLSE
Data de listagemMay 18, 2016
CEOMr. Paul A. Laviolette
Um total de
0.00
USD foi distribuído em dividendos nos últimos 5 anos.

Sem dados